Mednext Biotech Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Mednext Biotech Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $2.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mednext Biotech Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $2.6M Trade | TransData Nexus

Mednext Biotech Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $2.6M Total Trade · DGFT Verified

Mednext Biotech Limited is an Indian pharmaceutical exporter with a total trade value of $2.6M across 3 products in 3 therapeutic categories. Based on 54 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ofloxacin ($1.3M), Ciprofloxacin ($1.3M), Collagen ($41.8K).

Mednext Biotech Limited — Export Portfolio & Destination Treemap

Mednext Biotech Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Mednext Biotech Limited? — Company Overview & Market Position

Mednext Biotech Limited is a public limited company incorporated on August 17, 2012, in Udaipur, Rajasthan, India. The company is registered under the Corporate Identification Number (CIN) U24232RJ2012PLC039813. It has an authorized capital of ₹2.00 crore and a paid-up capital of ₹1.00 crore. Mednext Biotech Limited specializes in the manufacturing and marketing of pharmaceutical products, offering a diverse range of formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans various therapeutic categories, such as antibiotics, advanced antibiotics, and nutritional supplements.

The registered office of Mednext Biotech Limited is located at 1st Floor, 30 Mahaveer Nagar New Bhupalpura, Udaipur, Rajasthan, 313001, India. As of the latest available data, the company employs a workforce of 33 professionals. Mednext Biotech Limited is unlisted and operates as a non-government company limited by shares.

What Does Mednext Biotech Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ofloxacin$1.3M 2

Product Portfolio — Top 3 by Export Value

Mednext Biotech Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ofloxacin	Advanced Antibiotics	$1.3M	26	0.4%	11
2	Ciprofloxacin	Antibiotics	$1.3M	25	0.4%	10
3	Collagen	Nutritional Supplements	$41.8K	3	1.8%	8

Mednext Biotech Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $2.6M. The top category is Advanced Antibiotics (50.2% of portfolio), followed by Antibiotics (48.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Mednext Biotech Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Mednext Biotech Limited operates state-of-the-art manufacturing facilities in Udaipur, Rajasthan, India. These facilities are WHO-GMP qualified and certified, ensuring adherence to international quality standards. The manufacturing plant specializes in producing a wide range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company also offers nutraceuticals, Ayurvedic products, and cosmetics, catering to diverse healthcare needs.

3Key Leadership

Mednext Biotech Limited is led by a team of experienced professionals. Mr. Anil Kumar Vyas serves as the Director, bringing over 30 years of experience in the pharmaceutical sector. Dr. Neelam Vyas, holding a master's degree in Geography and a doctorate in Environmental Geography, is also a Director, overseeing the financial operations of the organization. Other key executives include Shriansh Vyas, appointed as an Additional Director on February 8, 2025, and Sunil Chittora, who joined as a Director on February 3, 2018.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Mednext Biotech Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Mednext Biotech Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company holds WHO-GMP certifications, which are recognized by regulatory authorities in these regions, facilitating market access. While specific regulatory filings and approvals in these markets are not detailed in the available sources, the WHO-GMP certification indicates compliance with international manufacturing standards, enhancing the company's credibility in these markets.

2Emerging Markets

Mednext Biotech Limited has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification enables it to meet the regulatory requirements of these regions, facilitating market entry and acceptance. By adapting its product offerings to the specific healthcare needs of various cultures, Mednext Biotech Limited aims to provide affordable and quality healthcare solutions globally.

3Geographic Strategy

Mednext Biotech Limited's geographic strategy demonstrates a balanced approach, with a significant focus on both domestic and international markets. The company's substantial export value of $2.6 million USD across 54 shipments indicates a strong international presence. The portfolio concentration, with the top five products accounting for 100% of exports, suggests a strategic focus on key products. This approach mitigates concentration risk and aligns with the company's mission to provide affordable healthcare solutions worldwide.

Mednext Biotech Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Mednext Biotech Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. However, the company's WHO-GMP certification indicates adherence to international manufacturing standards, which is a prerequisite for FDA approvals. To obtain detailed information on FDA approvals and inspection history, it is recommended to consult the FDA's official database or contact the company directly.

2WHO & EU GMP

Mednext Biotech Limited holds WHO-GMP certification, ensuring compliance with international manufacturing standards. This certification facilitates market access in various regions, including the European Union. While specific EU GMP certificates or EDQM status are not detailed in the available sources, the WHO-GMP certification serves as a recognized standard in the pharmaceutical industry, enhancing the company's credibility in regulated markets.

3CDSCO & Indian Regulatory

Mednext Biotech Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Mednext Biotech Limited operates in a competitive pharmaceutical industry, with key competitors in overlapping categories such as antibiotics, advanced antibiotics, and nutritional supplements. While specific market share comparisons and head-to-head analyses are not detailed in the available sources, the company's focus on quality manufacturing, as evidenced by its WHO-GMP certification, positions it favorably in the market. The company's strategic focus on key products, as indicated by its export portfolio concentration, suggests a targeted approach to market competition.

2Key Differentiators

Mednext Biotech Limited's key differentiators include its WHO-GMP certification, which ensures adherence to international manufacturing standards, and its diverse product portfolio encompassing tablets, capsules, syrups, injections, nutraceuticals, Ayurvedic products, and cosmetics. The company's strategic focus on key products, with the top five products accounting for 100% of exports, indicates a targeted approach to market needs.

3Strategic Position

Mednext Biotech Limited's current strategic direction emphasizes the manufacturing and marketing of a diverse range of pharmaceutical products, including generics, specialty products, and nutraceuticals. The company's WHO-GMP certification and focus on quality manufacturing underscore its commitment to meeting international standards. Looking ahead, Mednext Biotech Limited aims to expand its global footprint by adapting its product offerings to the specific healthcare needs of various cultures, thereby enhancing its strategic position in the global pharmaceutical market.

Buyer Due Diligence Brief — Evaluating Mednext Biotech Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Mednext Biotech Limited demonstrates a strong track record in pharmaceutical manufacturing, as evidenced by its WHO-GMP certification and diverse product portfolio. The company's export volume of $2.6 million USD across 54 shipments indicates consistent international trade activity. The portfolio concentration, with the top five products accounting for 100% of exports, suggests a focused and reliable supply chain. These factors collectively indicate Mednext Biotech Limited's reliability as a supplier in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications when considering Mednext Biotech Limited as a supplier:

WHO-GMP Certification: This certification ensures that the manufacturing processes meet international quality standards. Verification can be done by requesting a copy of the certificate from the company or consulting the WHO's official records.

EU GMP Certificate: If applicable, this certificate indicates compliance with European manufacturing standards. Verification can be done by requesting a copy of the certificate from the company or consulting the European Medicines Agency (EMA).

Frequently Asked Questions — Mednext Biotech Limited

How many pharmaceutical products does Mednext Biotech Limited export from India?

Mednext Biotech Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Ofloxacin ($1.3M), Ciprofloxacin ($1.3M), Collagen ($41.8K). Total export value is $2.6M.

What is Mednext Biotech Limited's total pharmaceutical export value?

Mednext Biotech Limited's total pharmaceutical export value is $2.6M, based on 54 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Mednext Biotech Limited cover?

Mednext Biotech Limited exports across 3 therapeutic categories. The largest are Advanced Antibiotics (50.2%, 1 products), Antibiotics (48.2%, 1 products), Nutritional Supplements (1.6%, 1 products).

Get Full Mednext Biotech Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.